We are live on ! Find out more
CP

Corbenic Partners Portfolio holdings

AUM $380M
1-Year Est. Return 10.47%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
-10.47%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$81.6M
AUM Growth
-$11.7M
Cap. Flow
-$16M
Cap. Flow %
-19.57%
Top 10 Hldgs %
59.09%
Holding
233
New
11
Increased
23
Reduced
42
Closed
20

Sector Composition

Rank Sector Weight
1 Technology 11.57%
2 Consumer Discretionary 9.32%
3 Communication Services 9.22%
4 Healthcare 7.08%
5 Industrials 4.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WFT
226
DELISTED
Weatherford International plc
WFT
-390
Closed -$2K
ECYT
227
DELISTED
Endocyte, Inc. Common Stock
ECYT
-32,639
Closed -$83K
CASC
228
DELISTED
Cascadian Therapeutics, Inc.
CASC
$0 ﹤0.01%
33
WPG
229
DELISTED
Washington Prime Group Inc.
WPG
-1
Closed
SFXE
230
DELISTED
SFX ENTERTAINMENT, INC COM
SFXE
$0 ﹤0.01%
1,950
ESV
231
DELISTED
Ensco Rowan plc
ESV
$0 ﹤0.01%
10
KMI.WS
232
DELISTED
Kinder Morgan Inc
KMI.WS
$0 ﹤0.01%
4,288
GCVRZ
233
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$0 ﹤0.01%
804

Similar funds

Corbenic Partners's Q1 2017 Portfolio in Review

As of Q1 2017, Corbenic Partners held 233 positions worth $81.6M, down 13% from $93.3M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Corbenic Partners withdrew a net $16M in Q1 2017, closing 20 positions and reducing 42 holdings. Its most notable exit was Endocyte, Inc. Common Stock, an estimated $83K position sold in full.

By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 13% a quarter earlier, followed by Consumer Discretionary and Communication Services.

Against the trend, Corbenic Partners opened a new position in iShares Russell 1000 ETF worth $49K.

  • Corbenic Partners's largest Q1 2017 buy was iShares Russell 1000 ETF: 374 shares worth $49K.
  • Corbenic Partners added most to Schwab US Broad Market ETF in Q1 2017, an estimated $2.03M increase.
  • Corbenic Partners's biggest Q1 2017 reduction was iShares Preferred and Income Securities ETF, cutting an estimated $2.84M.
  • Corbenic Partners fully exited Endocyte, Inc. Common Stock in Q1 2017, selling an estimated $83K.
  • Corbenic Partners's ten largest holdings make up 59% of its $81.6M portfolio in Q1 2017.
  • Corbenic Partners opened 11 new positions and closed 20 in Q1 2017.
  • Corbenic Partners's portfolio value fell 13% quarter-over-quarter to $81.6M.

Based on Corbenic Partners's 13F filing for Q1 2017, filed 26 Apr 2017.